Abstract Number: 2108 • 2017 ACR/ARHP Annual Meeting
Colchicine Treatment May be Protective Against Ventricular Arrhythmias in FMF Patients
Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease. Colchicine is used in FMF patients for preventing attacks and amyloidosis. There were conflicting reports as…Abstract Number: 375 • 2017 ACR/ARHP Annual Meeting
Controlled Discontinuation of Colchicine Therapy in Familial Mediterranean Fever Patients with Single MEFV Mutation
Background/Purpose: Familial Mediterranean fever (FMF) traditionally has been considered an autosomal recessive disease; however, the diagnosis remains predominantly clinical, since mutations cannot always be identified…Abstract Number: 262 • 2015 ACR/ARHP Annual Meeting
Canakinumab Therapy in Patients with Familial Mediterranean Fever
Background/Purpose: It has been reported that Canakinumab reduced the frequency of attacks in patients with Familial Mediterranean Fever (FMF) resistant to colchicine with no apparent…Abstract Number: 1230 • 2014 ACR/ARHP Annual Meeting
Efficacy of Interleukin-1 Targeting Drugs in Familial Mediterranean Fever Patients
Background/Purpose Familial Mediterranean fever (FMF) is an autosomal-recessive autoinflammatory disorder characterized by recurrent episodes of fever accompanied by sterile peritonitis. The most devastating complication of…Abstract Number: 1208 • 2013 ACR/ARHP Annual Meeting
Canakinumab In Patients With FMF
Background/Purpose: In a recent pilot study, it was reported that Canakinumab reduced the frequency of attacks in 9 patients with Familial Mediterranean Fever (FMF) resistant…